Dicerna Pharmaceuticals, Inc. (DRNA) Reaches New 12-Month High at $7.27

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares hit a new 52-week high on Thursday . The stock traded as high as $7.27 and last traded at $0.00, with a volume of shares changing hands.

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 price target (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a research report on Friday. ValuEngine raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $6.25 price target on the stock in a research report on Monday, October 23rd. Finally, Chardan Capital reissued a “hold” rating on shares of Dicerna Pharmaceuticals in a research report on Monday, August 14th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $6.81.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 210.01%. The company had revenue of $0.47 million during the quarter. During the same quarter in the prior year, the firm earned ($0.68) earnings per share. Dicerna Pharmaceuticals’s revenue was up 192.6% compared to the same quarter last year. equities research analysts predict that Dicerna Pharmaceuticals, Inc. will post -3.13 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of DRNA. UBS Group AG lifted its position in Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 1,599 shares during the last quarter. Renaissance Technologies LLC lifted its position in Dicerna Pharmaceuticals by 2.4% in the first quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock valued at $1,423,000 after buying an additional 9,818 shares during the last quarter. Paloma Partners Management Co lifted its position in Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock valued at $544,000 after buying an additional 53,131 shares during the last quarter. Bourgeon Capital Management LLC lifted its position in Dicerna Pharmaceuticals by 188.9% in the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 25,500 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 2,094 shares during the last quarter. 55.94% of the stock is currently owned by institutional investors.

WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/11/04/dicerna-pharmaceuticals-inc-drna-reaches-new-12-month-high-at-7-27.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

What are top analysts saying about Dicerna Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dicerna Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit